The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
1don MSN
Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
picture alliance / Contributor / Getty Images Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
An injection pen of Zepbound, Eli Lilly’s ... be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine Wegovy this Wednesday. Lilly attributed the shortfall ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback